Osborn Williams & Donohoe LLC Sells 675 Shares of Novartis AG (NVS)
Osborn Williams & Donohoe LLC decreased its holdings in shares of Novartis AG (NYSE:NVS) by 1.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 50,238 shares of the company’s stock after selling 675 shares during the period. Osborn Williams & Donohoe LLC’s holdings in Novartis were worth $4,328,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds have also modified their holdings of NVS. A.R.T. Advisors LLC bought a new stake in shares of Novartis during the 1st quarter valued at $1,293,000. Ancora Advisors LLC lifted its stake in shares of Novartis by 18.3% during the 1st quarter. Ancora Advisors LLC now owns 6,232 shares of the company’s stock valued at $504,000 after buying an additional 963 shares in the last quarter. LPL Financial LLC lifted its stake in shares of Novartis by 13.5% during the 1st quarter. LPL Financial LLC now owns 110,279 shares of the company’s stock valued at $8,916,000 after buying an additional 13,126 shares in the last quarter. Mariner LLC purchased a new position in shares of Novartis during the 1st quarter valued at $462,000. Finally, Guggenheim Capital LLC lifted its stake in shares of Novartis by 2.7% during the 1st quarter. Guggenheim Capital LLC now owns 43,471 shares of the company’s stock valued at $3,515,000 after buying an additional 1,138 shares in the last quarter. 10.94% of the stock is owned by hedge funds and other institutional investors.
A number of research analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of Novartis from a “sell” rating to a “hold” rating in a research note on Tuesday, June 19th. ValuEngine upgraded shares of Novartis from a “strong sell” rating to a “sell” rating in a research note on Thursday, July 19th. Citigroup upgraded shares of Novartis from a “neutral” rating to a “buy” rating in a research note on Tuesday, September 11th. Guggenheim assumed coverage on shares of Novartis in a research note on Monday, October 8th. They set a “neutral” rating on the stock. Finally, DZ Bank restated a “buy” rating on shares of Novartis in a research note on Thursday, July 19th. Thirteen equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $86.90.
Shares of NVS traded down $0.34 during trading hours on Wednesday, reaching $85.38. 369,071 shares of the stock traded hands, compared to its average volume of 1,747,680. The company has a debt-to-equity ratio of 0.30, a quick ratio of 0.89 and a current ratio of 1.15. Novartis AG has a 52-week low of $72.30 and a 52-week high of $94.19. The stock has a market cap of $199.67 billion, a price-to-earnings ratio of 17.70, a price-to-earnings-growth ratio of 1.80 and a beta of 0.83.
Novartis (NYSE:NVS) last announced its quarterly earnings results on Wednesday, July 18th. The company reported $1.29 EPS for the quarter, topping the consensus estimate of $1.27 by $0.02. The business had revenue of $13.16 billion for the quarter, compared to analysts’ expectations of $12.93 billion. Novartis had a net margin of 27.06% and a return on equity of 16.05%. The business’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.22 EPS. On average, equities research analysts predict that Novartis AG will post 5.17 earnings per share for the current year.
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines.
See Also: How is inflation measured?
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.